



Recent Trends in Oligonucleotide Based Therapies

Guest Editors:

Dr. Andreia F. Jorge

Dr. Santiago Grijalvo

Prof. Dr. Ramon Eritja

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides, mainly antisense DNA and small interfering RNA, with several already hitting the market. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19 pandemic. These molecules have the power to tackle targets that are usually considered to be “undruggable” by blocking the translation or transcription of a specific gene by stimulating the degradation of a particular messenger RNA. So far, multiple technologies have been developed to enhance oligonucleotide pharmacokinetics and pharmacodynamics. The most commonly used strategies include chemical modification, conjugation to cell-targeting moieties, and nanoparticle formulation. However, despite all of the progress that has been made, their rapid degradation in biological fluids along with the difficulty of crossing physiological barriers make cell delivery a hard task to achieve, and there is still a need for more competent delivery approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
[X@MDPIpharma](https://twitter.com/MDPIpharma)